Patient cases

Return to all patient cases

*Not based on actual patient.

Meet Jane:

Age 60
Stage IV recurrent colon cancer
KRAS wild-type

Meet Jane*

Jane is a 60-year-old woman who was diagnosed with stage IIb, KRAS wild-type, right-sided colon cancer. The cancer returned 3 years after completing adjuvant capecitabine with unresectable lung and liver metastases.

Disease history

  • Following diagnosis with stage IIb, right-sided colon cancer, she was successfully treated with total resection and 6 months of adjuvant capecitabine
  • Three years following the completion of adjuvant therapy, she was found to have unresectable lung and liver metastases
  • KRAS wild-type with no evidence of microsatellite instability or defective mismatch repair
  • She was treated with FOLFOX + bevacizumab regimen and had PFS of 8 months
  • She was subsequently treated with irinotecan + cetuximab for 5 months until disease progression

Relevant medical history

  • Hypertension well controlled with diuretic/beta-blocker therapy (BP: 116/78 mm Hg)
  • ECOG performance status: 1

Treatment options for this patient

Potential treatment regimen for a patient with stage IV, KRAS wild-type, right-sided colon cancer.

A possible treatment pathway for Jane1†


The treatment regimens shown represent just 1 possible treatment approach for this patient. According to NCCN Guidelines®, a number of alternative treatment plans could also be used.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.1.2020. © 2019 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

ACT IN TIME in previously treated patients with mCRC to help the survival potential of their treatment journey2,3

STIVARGA® (regorafenib) has been shown to be effective in patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild-type, an anti-EGFR therapy.2,3

Significant improvement in overall survival (OS) in a phase 3 trial

  • In the pivotal CORRECT trial, STIVARGA demonstrated a 6.4-month (95% CI, 5.8-7.3) overall survival (OS) rate in previously treated patients with mCRC, compared to 5.0 months (95% CI, 4.4-5.8) for placebo2
    • 23% reduction in the risk of death with STIVARGA (HR=0.77 [95% CI, 0.64-0.94; P=0.0102])2
    • There were 275 deaths out of 505 patients treated with STIVARGA (55%) vs 157 deaths out of 255 patients treated with placebo (62%)2

Significant improvement in progression-free survival (PFS) in a phase 3 trial

  • In the CORRECT trial, STIVARGA was associated with a 51% reduction in risk of progression or death compared to placebo (HR=0.49 [95% CI, 0.42-0.58; P<0.0001])2
    • Median PFS was 2.0 months (95% CI, 1.9-2.3) compared to 1.7 months (95% CI, 1.7-1.8) for placebo2
    • There were 417 deaths out of 505 patients treated with STIVARGA (83%) vs 231 deaths out of 255 patients treated with placebo (91%)2

Considerations when starting patients on STIVARGA

  • Select inclusion criteria3:
    • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
    • Life expectancy of at least 3 months
    • Adequate bone marrow, liver, and renal function
  • Help patients reach the first tumor assessment by monitoring adverse events frequently3,4
    • Monitor adverse events within the first week and every 2 weeks thereafter, or more often if needed

In the CORRECT trial3:

  • 27% (n=135) and 25% (n=63) of patients received ≤2 lines of prior systemic therapy in the STIVARGA (n=505) and placebo (n=255) arms, respectively
  • 26% of patients received cytotoxic therapy after STIVARGA

CORRECT (COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy) was a large, international, placebo-controlled, double-blind, randomized (2:1), phase 3 trial that evaluated the efficacy and safety of STIVARGA in patients with mCRC who had progressed after all approved standard therapies (N=760).2,3